Joseph Paul Eder MD

Professor of Medicine (Medical Oncology)

Specialties & Subspecialties

Cancer Center, Yale

Medical Oncology: Early Drug Development Program

Education & Training

  • M.D., Georgetown University School of Medicine (1978)
  • Residency, Georgetown University Hospital , Internal Medicine (1979 - 1981)
  • Fellowship, Georgetown University Hospital , Medical Oncology (1981 - 1982)
  • Fellowship, Beth Israel Hospital , Oncology/Hematology (1982 - 1985)

Patient Care

Accepts New Patients? Yes | Patient Type: Adult | Accepts referrals from patients


Clinical Interests

Some particular areas of past and present involvement in the development of novel therapeutics include high dose chemotherapy, the modulation/ reversal of drug resistance, growth factors, vaccines, signal transduction pathway inhibitors, cell cycle inhibitors, and the therapeutic use of antiangiogenisis agents. In this area, I have interest in developing pharmacodynamic markers of antiangiogenic effects in the clinic including MRI and PET imaging, circulating endothelial cells, monitoring interstitial fluid pressures and the evaluation of tumor biopsies after therapy. The clinical role of pathways to resistance is an area of interest and I have led clinical trials of HGF/MET inhibitors combined with VEGF-targeted therapies.


Board Certifications

  • Hematology, Internal Medicine, Board Certified (1984)
  • Internal Medicine, Board Certified (1981)
  • Medical Oncology, Board Certified (1983)

Clinical Trials

ConditionsStudy Title
Hepatocellular Carcinoma and LiverMulticenter, Placebo-Controlled, Randomized Pilot Study of the Effect of Sorafenib on Portal Pressure in Patients with Cirrhosis, Significant Portal Hypertension and HCC Treated with Ablative Therapy and/or Transarterial Chemoembolization
Colorectal Cancer and ColonA Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer (CALGB 80702)
Breast Cancer (ER, PR, and HER2 negative), Colorectal Cancer, Endometrial Cancer, Gastric Adenocarcinoma, Glioblastoma Multiforme, Head/ Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Prostate Cancer, Brain and Nervous System, Breast - Female, Breast - Male, Colon, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Other Female Genital, Ovary, Prostate, Rectum, and StomachA Phase I/IIa, First Time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency
Adenocarcinoma of the Gastroesophageal Junction, Gastric Cancer, Esophagus, and StomachA RANDOMIZED, MULTICENTER, ADAPTIVE PHASE II/III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE (T-DM1) VERSUS TAXANE (DOCETAXEL OR PACLITAXEL) IN PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC HER2-POSITIVE GASTRIC CANCER, INCLUDING ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION
Bladder, Breast - Female, Lung, Pancreas, and StomachA Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

More Clinical Trials...

Edit Profile